Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > Board Recommends Continuation of Medidur(TM) Trial

March 20th, 2006

Board Recommends Continuation of Medidur(TM) Trial

Abstract:
Alimera Sciences Inc., an emerging ophthalmic pharmaceutical company, and pSivida Limited, a global
bio-nanotech company, announced today that following a planned interim review, an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of its Phase 3 clinical trial of Medidur(TM).

Source:
newswire.ca

Bookmark:

Related News Press

Nanomedicine

How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013

MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013

Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013

Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013

Announcements

JPK reports on single molecule research at IISER Pune in India using AFM and CellHesion techniques May 21st, 2013

Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013

International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013

Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013